HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (8) Citing Articles via Google Scholar Google Scholar Articles by Miceli, J. J. Articles by Tensfeldt, T. G. Search for Related Content PubMed PubMed Citation Articles by Miceli, J. J. Articles by Tensfeldt, T. G. Social Bookmarking                         What's this?

Pharmacokinetics, Safety, and Tolerability of Intramuscular Ziprasidone in Healthy Volunteers

From Pfizer Global Research and Development, Groton, Connecticut (Dr Miceli, Mr Tensfeldt); Pfizer Global Research and Development, La Jolla, California (Dr Wilner); and Hennepin County Medical Center and DaVita Clinical Research Unit, Minneapolis, Minnesota (Dr Swan).

Little has been published regarding the pharmacokinetics of the intramuscular (IM) formulation of Ziprasidone. The authors report results from 2 early phase I studies in healthy volunteers: a trial of single 5-, 10-, or 20-mg IM doses of ziprasidone in 24 subjects and an open-label 3-way crossover trial of 5-mg intravenous (IV), 5-mg IM, and 20-mg oral ziprasidone in 12 subjects. Absorption of IM ziprasidone was rapid (T_max < 1 hour). The IM pharmacokinetic profile was consistent between studies and linear, with dose-related increases in exposure observed. The mean IM elimination t_1/2 was short and approximately 2.5 hours. The mean bioavailability for the 5-mg IM ziprasidone dose was approximately 100%. Adverse events were generally mild to moderate, and no subjects were discontinued from the study. No significant effects on renal function or other laboratory values were noted. These results support the use of IM ziprasidone in treating acutely agitated patients with schizophrenia.

Key Words: Acute schizophrenia • antipsychotic • pharmacokinetics • safety • tolerability • ziprasidone

Address for reprints: Jeffrey J. Miceli, Pfizer Inc, Pfizer Global Research and Development, 50 Pequot Avenue, MS 6025-B2233, New London, CT 06320.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. L Bentley, F. H Biscardi, C. Butcher, and A. Levitov Inadvertent Administration of Intravenous Ziprasidone Leading to Bradycardia and QT Interval Prolongation Ann. Pharmacother., June 1, 2008; 42(6): 902 - 903. [Full Text] [PDF]

				L. Wu, J. C. Shryock, Y. Song, and L. Belardinelli An Increase in Late Sodium Current Potentiates the Proarrhythmic Activities of Low-Risk QT-Prolonging Drugs in Female Rabbit Hearts J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 718 - 726. [Abstract] [Full Text] [PDF]